<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1726-8958</journal-id>
<journal-title><![CDATA[Revista Médica La Paz]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. La Paz]]></abbrev-journal-title>
<issn>1726-8958</issn>
<publisher>
<publisher-name><![CDATA[Colegio Médico de La Paz]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1726-89582023000200077</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[USO DE INHIBIDORES DE SGLT 2 EN PACIENTES CON NEFROPATÍA DIABÉTICA]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Urquizo Ayala]]></surname>
<given-names><![CDATA[Guillermo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Henao Sanjines]]></surname>
<given-names><![CDATA[Milenca Valentina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital de Clínicas Unidad de Medicina Interna ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de Clínicas  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>29</volume>
<numero>2</numero>
<fpage>77</fpage>
<lpage>79</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S1726-89582023000200077&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S1726-89582023000200077&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S1726-89582023000200077&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El tratamiento antidiabético oral ha sido un reto en el manejo de la diabetes mellitus. Los pacientes con algún grado de enfermedad renal crónica corren serios riesgos de hipoglucemia, sin embargo, los inhibidores del transportador de glucosa SGLT2 suponen un nuevo abordaje terapéutico de la diabetes mellitus tipo 2. Estudios en modelos experimentales de diabetes han demostrado que la inducción de glucosuria revierte la glucotoxicidad, restaura la normoglucemia, y mejora el funcionamiento de la célula beta y la sensibilidad a la insulina. Por lo tanto, se constituyen en una alternativa segura en estos pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Oral antidiabetic treatment has been a challenge in the management of diabetes mellitus in patients with some degree of chronic kidney disease due to the constant risks of hypoglycemia; however, glucose transporter SGLT2 inhibitors represent a new therapeutic approach to diabetes mellitus. Type 2, studies in experimental models of diabetes have shown thatthe induction of glycosuria reverses glucotoxicity, restores normoglycemia, and improves beta cell function and insulin sensitivity.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[antidiabéticos orales]]></kwd>
<kwd lng="es"><![CDATA[enfermedad renal crónica]]></kwd>
<kwd lng="es"><![CDATA[hipoglucemia]]></kwd>
<kwd lng="en"><![CDATA[Oral antidiabetic]]></kwd>
<kwd lng="en"><![CDATA[chronic kidney disease]]></kwd>
<kwd lng="en"><![CDATA[hypoglycemia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Diagnosis and Classification of Diabetes Mellitus]]></article-title>
<source><![CDATA[Diabetes Care 1]]></source>
<year>2011</year>
<volume>34</volume>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samsu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetic Nephropathy Challenges in Pathogenesis, Diagnosis, and Treatment]]></article-title>
<source><![CDATA[Biomed Res Int]]></source>
<year>2021</year>
<volume>2021</volume>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arroyo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Goicoechea Diezandino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacos antidiabeticos en la Enfermedad Renal Cronica]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Lorenzo]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez Gomez]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<source><![CDATA[Nefrologia al dia]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>Revistanefrologia.com</collab>
<article-title xml:lang=""><![CDATA[MANEJO PRACTICO DE ANTIDIABETICOS ORALES EN PACIENTES CON ENFERMEDAD RENAL]]></article-title>
<source><![CDATA[Revistanefrologia.com]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salinas-Lezama]]></surname>
<given-names><![CDATA[Erika]]></given-names>
</name>
<name>
<surname><![CDATA[Seniscal-Arredondo]]></surname>
<given-names><![CDATA[Daniel]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcon-Sotelo]]></surname>
<given-names><![CDATA[Alejandra]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz-Greene]]></surname>
<given-names><![CDATA[Enrique Juan]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Weber]]></surname>
<given-names><![CDATA[Federico Leopoldo]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectos nefrologicos de los SGLT2. .Que sabemos hasta ahora?]]></article-title>
<source><![CDATA[Medicina interna de Mexico]]></source>
<year>2019</year>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>379-88</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez Lopez]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez Albarran]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Cano Megias]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia]]></source>
<year>2010</year>
<volume>30</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>618-25</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heerspink]]></surname>
<given-names><![CDATA[HJL]]></given-names>
</name>
<name>
<surname><![CDATA[Stefansson]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
<name>
<surname><![CDATA[Chertow]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Correa-Rotter]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
<name>
<surname><![CDATA[Lindberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rossing]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Toto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Langkilde]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Wheeler]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<collab>DAPA-CKD Investigators</collab>
<article-title xml:lang=""><![CDATA[Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2020</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>274-82</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
